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Correspondence thing ?), for which you condemn prophylactic antibiotics. Our experience of 22 cases of gas gangrene suggests that this condition was unexpected and arose from a variety of orthopaedic operations-only four had had amputations.
We find it difficult to understand how you can avoid the mention of hyperbaric oxygen in the management of this dreadful condition. An earlier leading article' was followed shortly afterwards by a letter' in which it was quoted that a multi-centre investigation of 200 cases treated by hyperbaric oxygen revealed a mortality rate of 2-9%, excluding those moribund on admission and dying within 24 hours.' We reported 16 Table I in our report on prevalence rates of cervical carcinoma in situ for women using the diaphragm or contraceptive oral steroids (26 July, p. 195), draws conclusions that result from a misreading of the paper and require correction.
The Planned Parenthood Centers of New York City had been in operation for many years at the time this study was begun and the first cytological examinations were carried out. Column O+ in Table I refers to the uncorrected prevalence rates that were found on the initial survey for the total of all women choosing and/or using oral steroids or diaphragms for all lengths of time. We had thought that this was clearly stated in the caption and emphasized in a footnote to give a history of using some type of contraceptive previously. Approximately 30% of the women who chose oral steroids on their first visit indicated that they had used them in the past, although they often could not recall for how long or when. Thus, even the newcomers who are part of the population in column 0+ of Table I include a very significant proportion of steroid " choosers " who were actually " users " before they came. I think it is not possible to find a sizable population of sexually active women today in the United States (or in the United Kingdom) who have not been using some form of contraceptive. For that reason prevalence rates of disease are unavailable for a "control" group of women using no contraceptive, and meaningful differences must be sought in comparisons between matched populations where the contraceptive used is known. This is what we have done. Clearly, the matter of free choice of contraceptive is important and may be influenced by unknown factors affecting the probability of developing carcinoma. We have so stated in our discussion of results. Our next step is to follow the incidence rates of disease in matched populations that are initially normal, and will include a third group of women using another form of contraception (intrauterine device).
So far, nearly 50,000 women have been examined, and large matched populations of normal women who are using the diaphragm, oral steroids, or an intrauterine device for contraception are available. We are prepared to continue for at least five to 10 yeavs more to determine incidence rates of the disease in these three different groups. If there are clinically meaningful differences, they should be apparent within that time. Because of differences between the study and control groups on many important variables the data presented are relatively meaningless, except for the groups matched on the five vectors representing the important variables associated with cervical cancer risk. The twofold difference indicated by these data between oral contraceptive and diaphragm users hinges on the validity of the carcinoma in situ prevalence-rate deterinations. Prevalence rates for carcinoma in situ can only come from the findings of cytological examinations performed for the first
